10-Q: AbbVie Q3 2025 Earnings: Strategic Investments Impact Profit

AbbVie reports robust third-quarter 2025 revenue growth driven by immunology and neuroscience, but net earnings significantly declined due to substantial R&D investments and impairment charges.

Summary

• Worldwide net revenues for the nine months ended September 30, 2025, increased 8.0% to $44,542 million (8.2% at constant currency) compared to $41,232 million in the prior year.
• Net earnings attributable to AbbVie Inc. for the nine months ended September 30, 2025, decreased to $2,410 million from $4,300 million in the prior year.
• Diluted earnings per share for the nine months ended September 30, 2025, decreased to $1.34 from $2.41 in the prior year.
• Operating earnings for the nine months ended September 30, 2025, were $10,531 million, a slight decrease from $10,627 million in the prior year.
• Cash flows from operating activities for the nine months ended September 30, 2025, increased to $13,812 million from $11,758 million in the prior year.
• Acquired IPR&D and milestones expense significantly increased to $3,751 million for the nine months ended September 30, 2025, from $1,183 million in the prior year, including $1.9 billion for Capstan Therapeutics and $700 million for Ichnos Glenmark Innovation.
• The company recorded pre-tax impairment charges of $847 million in the third quarter of 2025 related to the discontinuation of Resonic and reduced investment in Durysta.
• The effective tax rate for the nine months ended September 30, 2025, was 39%, up from 28% in the prior year, primarily due to business development activities and changes in fair value of contingent consideration.
• AbbVie increased its quarterly cash dividend by 5.5% from $1.64 to $1.73 per share, effective with the dividend payable on February 17, 2026.
• The company completed several acquisitions and licensing agreements, including Gilgamesh Pharmaceuticals (post-Q3), Nimble Therapeutics ($288 million), Capstan Therapeutics ($2.1 billion), Ichnos Glenmark Innovation ($700 million upfront), ADARx Pharmaceuticals ($335 million upfront), and Gubra A/S ($350 million upfront).
• Settled litigation with all generic manufacturers for Rinvoq, with no generic entry expected prior to April 2037 in the United States, assuming pediatric exclusivity.

Sentiment

Score: 5

Explanation: While revenue growth from key products and strategic pipeline investments are positive, the substantial decline in net earnings and diluted EPS, coupled with a shift to a negative total equity position, indicates significant short-term financial pressure. The high effective tax rate and impairment charges further weigh on profitability. The long-term potential from the pipeline and Rinvoq patent settlement provides some balance, but current financial results are a concern.

Positives

• Worldwide net revenues increased 9.1% (reported) and 8.4% (constant currency) for the three months ended September 30, 2025, and 8.0% (reported) and 8.2% (constant currency) for the nine months ended September 30, 2025.
• Skyrizi net revenues grew 46% (Q3) and 58% (9M) at constant currency, driven by strong market share uptake and market growth.
• Rinvoq net revenues grew 34% (Q3) and 43% (9M) at constant currency, also due to strong market share uptake and market growth.
• Qulipta net revenues increased 63% (Q3 and 9M) at constant currency, showing continued strong market share uptake and growth.
• Ubrelvy net revenues increased 32% (Q3) and 33% (9M) at constant currency, driven by market share uptake and growth.
• Botox Therapeutic net revenues increased 16% (Q3) and 15% (9M) at constant currency, due to market share uptake and market growth.
• Cash flows from operating activities increased to $13,812 million for the nine months ended September 30, 2025, from $11,758 million in the prior year.
• Strategic pipeline expansion through acquisitions and licensing agreements, including Gilgamesh Pharmaceuticals, Nimble Therapeutics, Capstan Therapeutics, Ichnos Glenmark Innovation, ADARx Pharmaceuticals, and Gubra A/S.
• Positive clinical trial results for Rinvoq in alopecia areata and non-segmental vitiligo, and demonstrated superiority versus Humira in rheumatoid arthritis in the SELECT-SWITCH study.
• Regulatory approvals for Rinvoq (GCA, updated ulcerative colitis/Crohn's indication), Emrelis (lung cancer), Emblaveo (antibiotic), and Mavyret (HCV label expansion).
• Settlement of Rinvoq patent litigation, delaying generic entry until April 2037 in the US, assuming pediatric exclusivity.
• Increased quarterly dividend by 5.5% to $1.73 per share, signaling confidence in future performance.
• Expected favorable impact on cash tax payments in the current year from the One Big Beautiful Bill Act of 2025.
• Initiated construction of a new active pharmaceutical ingredient facility in Illinois and expanded biologics manufacturing and R&D capacity in Massachusetts.

Negatives

• Net earnings attributable to AbbVie Inc. significantly decreased to $186 million in Q3 2025 from $1,561 million in Q3 2024, and to $2,410 million in 9M 2025 from $4,300 million in 9M 2024.
• Diluted EPS decreased to $0.10 in Q3 2025 from $0.88 in Q3 2024, and to $1.34 in 9M 2025 from $2.41 in 9M 2024.
• Operating earnings slightly decreased to $10,531 million in 9M 2025 from $10,627 million in 9M 2024.
• Humira net revenues decreased 56% (Q3) and 55% (9M) at constant currency due to direct biosimilar competition.
• Acquired IPR&D and milestones expense increased substantially to $2,680 million in Q3 2025 from $82 million in Q3 2024, and to $3,751 million in 9M 2025 from $1,183 million in 9M 2024, impacting profitability.
• Intangible asset impairment charges of $847 million were recorded in Q3 2025 for Resonic (discontinued) and Durysta (reduced investment).
• Change in fair value of contingent consideration liabilities increased to $5.1 billion for 9M 2025 from $3.5 billion for 9M 2024, contributing to higher other expense, net.
• The effective tax rate increased significantly to 74% in Q3 2025 and 39% in 9M 2025, primarily due to business development activities and contingent consideration changes.
• Total equity (deficit) shifted from a positive $3,364 million at December 31, 2024, to a negative $(2,599) million at September 30, 2025, primarily due to an increase in accumulated deficit from $(7,900) million to $(14,234) million.
• Imbruvica global revenues decreased 15% (Q3) and 12% (9M) at constant currency due to decreased demand and unfavorable pricing.
• Botox Cosmetic net revenues decreased 5% (Q3) and 7% (9M) at constant currency, primarily due to unfavorable pricing, lower market share, and decreased consumer demand in the US.
• Juvederm Collection net revenues decreased 3% (Q3) and 17% (9M) at constant currency, primarily due to decreased global consumer demand.
• The global Phase 3 VERONA trial evaluating Venclexta in combination with azacitidine for higher-risk myelodysplastic syndrome did not meet its primary endpoint of overall survival.

Risks

• Challenges to intellectual property rights and competition from other products, including biosimilars for Humira.
• Difficulties inherent in the research and development process, as evidenced by the Venclexta VERONA trial failure.
• Adverse litigation or government action, including Niaspan antitrust lawsuits, opioid litigation, Humira pricing class actions, breast implant product liability litigation, and ongoing tax disputes.
• Changes to laws and regulations applicable to the industry, such as pharmaceutical pricing pressures (e.g., most-favored-nation pricing, Inflation Reduction Act provisions) and new tax legislation.
• Impact of global macroeconomic factors, including economic downturns, international trade disruptions, disputes, and tariffs.
• Fair value measurements of contingent consideration liabilities rely on significant unobservable inputs and judgment, and changes to these inputs could materially impact financial position and results of operations.
• Concentration of credit risk, with three U.S. wholesalers accounting for 81% of total net accounts receivable and substantially all U.S. pharmaceutical product net revenues.

Future Outlook

AbbVie anticipates several regulatory submissions and data readouts from key clinical trials in the next 12 months, with multiple mid-stage programs expected to transition into late-stage development. The recently enacted One Big Beautiful Bill Act of 2025 is expected to have a favorable impact on cash tax payments in the current year. Generic entry for Rinvoq tablets in the United States is not expected prior to April 2037, assuming pediatric exclusivity is granted.

Management Comments

• Our mission is to discover and develop innovative medicines and products that solve serious health issues today and address the medical challenges of tomorrow while achieving top-tier financial performance through outstanding execution.
• We intend to execute our strategy by maximizing the benefits of a diversified revenue base with multiple long-term growth drivers, leveraging commercial strength and international infrastructure, continuing to invest in and expand our pipeline, and generating substantial operating cash flows to support R&D and return cash to shareholders.
• The new legislation (2025 Act) is expected to have a favorable impact on cash tax payments in the current year.
• Research and innovation are the cornerstones of our business, and our long-term success depends on our ability to continue to discover and develop innovative products and acquire or collaborate on compounds in development.

Industry Context

The biopharmaceutical industry continues to navigate challenges from intellectual property expirations and biosimilar competition, as seen with Humira's revenue decline. AbbVie's aggressive M&A and licensing strategy, including entering the obesity field with Gubra A/S, reflects a broader industry trend of companies seeking to diversify revenue streams and replenish pipelines to offset patent cliffs. Regulatory scrutiny on pharmaceutical pricing, such as the most-favored-nation (MFN) pricing initiative, remains a significant factor impacting the industry's operating environment.

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan violated federal and state antitrust laws and state unfair and deceptive trade practices.
• Approximately 380 lawsuits are pending against Allergan (an AbbVie entity) and several other manufacturers generally alleging improper promotion and sale of prescription opioid products, seeking compensatory and punitive damages.
• The Commissioner of Internal Revenue appealed a June 2025 United States Tax Court decision that granted AbbVie's motion for summary judgment concerning a $572 million income tax benefit recorded in 2014.
• A putative class action lawsuit, Camargo v. AbbVie Inc., alleges Humira's list price is excessive in violation of multiple states' unfair and deceptive trade practices statutes, seeking monetary damages and injunctive relief.
• Approximately 145 ALCL lawsuits and 1,300 other lawsuits are pending against various Allergan entities related to Biocell textured breast implants, seeking monetary damages, medical monitoring, and attorneys' fees.
• A putative class action lawsuit, Sheet Metal Workers Health Plan of Southern California, Arizona and Nevada v. AbbVie Inc., alleges AbbVie's rebating practices impair biosimilar competition with Humira in violation of federal and state antitrust laws.
• AbbVie filed litigation to enforce patent rights relating to upadacitinib (Rinvoq) against generic manufacturers, which was settled in September 2025, delaying generic entry until April 2037 in the US.
• AbbVie is seeking to enforce patent rights related to ubrogepant (Ubrelvy) against generic manufacturers, alleging infringement and seeking declaratory and injunctive relief.

Related Party Transactions

• Collaboration with Janssen Biotech, Inc. for Imbruvica: AbbVie and Janssen share pre-tax profits and losses equally from commercialization. Janssen's share of US profits was $235 million (Q3 2025) and $735 million (9M 2025), included in cost of products sold. AbbVie's share of international profits was $199 million (Q3 2025) and $619 million (9M 2025), included in net revenues.
• Collaboration with Genentech, Inc. for Venclexta: AbbVie shares equally with Genentech all pre-tax profits and losses from US development and commercialization. Genentech's share of US profits was $286 million (Q3 2025) and $790 million (9M 2025), included in cost of products sold. AbbVie pays royalties on Venclexta net revenues outside the United States.

Stakeholder Impact

• Shareholders are impacted by a significant decline in net earnings and EPS, but also benefit from a 5.5% increase in the quarterly dividend and continued stock repurchase program, with $2.9 billion remaining under authorization.
• Employees are affected by restructuring charges of $189 million for the nine months ended September 30, 2025, indicating ongoing operational adjustments, but also benefit from employee incentive awards related to acquisitions.
• Customers benefit from new product approvals (Emrelis, Emblaveo, Mavyret label expansion) and advancements in the pipeline, while Humira biosimilar competition may lead to more affordable treatment options.
• Creditors face increased debt levels due to new senior notes issuance ($4.0 billion) and term loan borrowings ($2.0 billion), but the company maintains strong operating cash flows and compliance with debt covenants.

Next Steps

• Assess the impact of adopting ASU No. 2024-03 (Expense Disaggregation Disclosures) and ASU No. 2023-09 (Income Taxes).
• Continue to assess the impact of the 2025 Act, including new healthcare provisions.
• Multiple mid-stage programs are expected to transition into late-stage programs in the next 12 months.
• Anticipate several regulatory submissions and data readouts from key clinical trials in the next 12 months.
• Continue construction of a new active pharmaceutical ingredient facility in Illinois and expansion of biologics manufacturing and R&D capacity in Massachusetts.
• The accounting impact of the Gilgamesh acquisition will be included in the consolidated financial statements beginning in the fourth quarter of 2025.
• The Commissioner of Internal Revenue appealed the US Tax Court decision regarding the 2014 income tax benefit.

Key Dates

Recommendation

While the significant decline in net earnings and diluted EPS is concerning, it is largely attributable to substantial strategic investments in R&D, acquisitions, and one-time impairment charges, rather than a fundamental deterioration of core business. The strong revenue growth from Skyrizi, Rinvoq, Qulipta, and Ubrelvy, coupled with the long-term patent protection for Rinvoq, demonstrates underlying strength and future growth potential. The increased dividend signals management's confidence. However, the ongoing impact of Humira biosimilar competition and the high effective tax rate warrant caution. A 'Hold' recommendation reflects the mixed financial performance in the short term, balanced by a strong pipeline and strategic positioning for long-term growth.

Keywords

AbbVie, Biopharmaceutical, Immunology, Neuroscience, Oncology, Aesthetics, Eye Care, SEC Filing, 10-Q, Earnings, Revenue, EPS, Pipeline, R&D, Acquisitions, Humira, Rinvoq, Skyrizi, Venclexta, Botox, Qulipta, Ubrelvy, Elahere, Imbruvica, Gilgamesh, Nimble, Capstan, Ichnos Glenmark, ADARx, Gubra, Patent Litigation, Biosimilars, Dividends, Corporate Governance